Recent years have seen growing international debate about the ethics of conducting medical research in developing countries. Although many of the issues at stake do not differ in kind from those in more developed countries, the limited resources available within developing countries may exacerbate the problems faced. In addition, imbalances in power between the stakeholders in research - which can include multinational pharmaceutical companies, publicly funded researchers, national governments, and participants - can increase the risk of exploitation of the more vulnerable parties.